Acute coronary syndrome pharmacotherapy data cluster

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Acute coronary syndrome pharmacotherapy data cluster

Identifying and definitional attributes

Metadata item type:	Data Set Specification			
METEOR identifier:	351876			
Registration status:	Health, Standard 01/10/2008			
DSS type:	Data Element Cluster			
Scope:	The pharmacotherapies collected in this data cluster are recommended for the management of acute coronary syndromes (ACS) in the national guidelines. The following pharmacotherapies are collected as part of this data cluster:			
	 Aspirin Angiotensin converting enzyme (ACE) inhibitor Angiotensin II receptor blocker Antithrombin Beta-blocker Clopidogrel Fibrinolytic Glycoprotein llb/llla receptor antagonist Statin The pharmacotherapy cluster collects information on the type of pharmacotherapies prescribed and the timing of each prescription.			
Source and reference attributes				
Steward:	The National Heart Foundation of Australia and The Cardiac Society of Australia and New Zealand			
Reference documents:	National Heart Foundation of Australia & Cardiac Society of Australia and New			

Reference documents: National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand. Guidelines for the management of acute coronary syndromes 2006. Med J Aust 2006; 184; S1-S32. © MJA 2006

Relational attributes

Implementation in Data Set Specifications:	Acute coronary syndrome (clinical) DSS Health, Superseded 01/09/2012
	Acute coronary syndrome (clinical) DSS Health, Superseded 02/05/2013
	Acute coronary syndrome (clinical) NBPDS 2013- Health, Standard 02/05/2013 Implementation start date: 01/07/2013

Metadata items in this Data Set Specification

Seq No.	Metadata item	Obligation	Max occurs
-	Person with acute coronary syndrome—pharmacotherapy type prescribed in hospital, code N[N]	Mandatory	10

DSS specific information:

Codes provided for each of those prescribed during this hospital presentation.

Seq No.	Metadata item	Obligation	Max occurs
-	Person with acute coronary syndrome—pharmacotherapy type taken post discharge from hospital, code N[N]	Mandatory	7
	DSS specific information:		
	To be provided at the follow-up visit following discharge from the hospital for each of the relevant pharmacotherapy types prescribed.		
-	Person-fibrinolytic drug administered, code N	Conditional	1
	Conditional obligation:		
	If prescribed, provide the fibrinolytic drug administered.		
-	Person-intravenous fibrinolytic therapy date, DDMMYYYY	Conditional	1
	Conditional obligation:		
	If prescribed, provide the date when the fibrinolytic therapy is administered.		
-	Person-intravenous fibrinolytic therapy time, hhmm	Conditional	1
	Conditional obligation:		
	If prescribed, provide the time when the fibrinolytic therapy is administered.		
-	Person—reason for non prescription of pharmacotherapy, code N	Conditional	9
	Conditional obligation:		
	To be provided for each of the pharmacotherapies listed in the data element ' <i>Pharmacotherapy type prescribed for acute coronary syndrome in hospital</i> ' not prescribed.		
-	Person—timing of ACE-inhibitor prescription, code N	Conditional	5
	Conditional obligation:		
	If prescribed, provide a phase for each time ACE-inhibitor therapy is prescribed.		
-	Person-timing of angiotensin II receptor blocker prescription, code N	Conditional	5
	Conditional obligation:		
	If prescribed, provide a phase for each time angiotensin II receptor blocker therapy is prescribed.		
-	Person—timing of antithrombin therapy prescription, code N	Conditional	4
	Conditional obligation:		
	If prescribed, provide a phase for each time antithrombin therapy is prescribed		
-	Person-timing of aspirin prescription, code N	Conditional	5
	Conditional obligation:		
	If prescribed, provide a phase for each time aspirin therapy is prescribed.		
-	Person-timing of beta-blocker prescription, code N	Conditional	5
	Conditional obligation:		
	If prescribed, provide a phase for each time beta-blocker therapy is prescribed.		

Seq No.	Metadata item	Obligation	Max occurs
-	Person—timing of clopidogrel prescription, code N	Conditional	5
	Conditional obligation:		
	If prescribed, provide a phase for each time clopidogrel therapy is prescribed.		
-	Person—timing of glycoprotein Ilb/Illa inhibitor prescription, code N	Conditional	4
	Conditional obligation:		
	If prescribed, provide a phase for each time glycoprotein IIb/IIIa inhibitor therapy is prescribed.		
-	Person—timing of statin prescription, code N	Conditional	5
	Conditional obligation:		

If prescribed, provide a phase for each time statin therapy is prescribed.